Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01400971 · ClinicalTrials.gov registry record
An Observational Study to Understand Challenges Associated With Progression of Insulin Therapy in Type 2 Diabetes
A clinical trial, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- 4,299
- Enrollment target
NCT01400971 is a clinical trial that has completed, run by Eli Lilly and Company. The registered enrollment target is 4,299 participants.
The verdict
NCT01400971 has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- 4,299 participants
- Enrollment target
Study Summary
The purpose of this study is to identify specific patient, physician, and health system related factors associated with the progression to a more intensive regimen from initial insulin therapy for patients with type 2 diabetes.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,299 participants |
| Start Date | 2011-07 |
| Est. Completion | 2015-09 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01400971
The ClinicalTrials.gov registry entry for NCT01400971 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 4,299 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT01400971 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01400971 about?
NCT01400971 is a clinical study titled "An Observational Study to Understand Challenges Associated With Progression of Insulin Therapy in Type 2 Diabetes". The purpose of this study is to identify specific patient, physician, and health system related factors associated with the progression to a more intensive regimen from initial insulin therapy for patients with type 2 diabetes.
What is the current status of trial NCT01400971?
This trial is currently completed. The enrollment target is 4,299 participants. The study started on 2011-07. Estimated completion is 2015-09.
Who is sponsoring clinical trial NCT01400971?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.